Gilteritinib
Chemical compound
From Wikipedia, the free encyclopedia
Gilteritinib, sold under the brand name Xospata, is an anti-cancer drug.[6]
| |
| Clinical data | |
|---|---|
| Trade names | Xospata |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619003 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C29H44N8O3 |
| Molar mass | 552.724 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mechanism of action
Gilteritinib acts as an inhibitor of FLT3, hence it is a tyrosine kinase inhibitor.[7]
History
Gilteritinib was developed by Astellas Pharma.
In April 2018, Astellas filed a new drug application with the Food and Drug Administration for gilteritinib for the treatment of adult patients with FLT3 mutation–positive (both ITD and TKD[8]) relapsed or refractory acute myeloid leukemia (AML).[9]
In November 2018, the FDA approved gilteritinib for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.[10][4] It is effective beyound second line of therapy.[11]
Gilteritinib was granted orphan drug status by the U.S. FDA, the European Commission (EC) and the Japan Ministry of Health, Labor and Welfare, for some AML patients.[12]
Gilteritinib was approved for medical use in Australia in March 2020.[13]
